Abstract
Purpose
To evaluate the impact of surgical waiting time (SWT) on outcomes of patients who underwent radical nephrectomy for stage II or higher renal cell carcinoma (RCC).
Methods
Of the 1,732 patients who underwent surgery for RCC between 1989 and 2007, medical records of 319 with clinical stage II or higher RCC without distant metastases were retrospectively reviewed. Ten patients with SWT greater than 3 months were excluded from analysis, and we compared pathological upstaging and survival rates between patients with SWT <1 month (234/319, 73.3 %) and 1–3 months (75/319, 23.5 %).
Results
Clinicopathological characteristics between two groups were not different except the presence of symptom. The pathological upstaging was higher in patients with SWT of 1–3 months but statistically not significant. SWT of 1–3 months was not an independent predictor of pathological upstaging, recurrence-free survival (RFS; p = 0.896), or cancer-specific survival (CSS; p = 0.737). On subgroup analysis by TNM stage (cT2NxcM0 and cT3-4NxcM0), SWT of 1–3 months was not an independent predictor of pathological upstaging and was not associated with RFS or CSS. SWT, treated as a continuous variable, was also not an independent predictor of outcome in any subgroup. Similar results were found in symptomatic patients.
Conclusions
The outcomes of patients with prolonged SWT did not differ from those of most patients who underwent nephrectomy within 1 month. In patients with stage II or higher RCC who underwent nephrectomy within 3 months after diagnosis, prolonged SWT was not an independent predictor of pathological upstaging, RFS, or CSS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, Sylvester R (2009) Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55(1):28–34
Chapin BF, Delacroix SE, Culp SH, Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG (2011) Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 60(5):964–971
Chapman TN, Sharma S, Zhang S, Wong MK, Kim HL (2008) Laparoscopic lymph node dissection in clinically node-negative patients undergoing laparoscopic nephrectomy for renal carcinoma. Urology 71(2):287–291
Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK (2010) Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 28(9):1502–1507
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474
Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC, Terris MK (2006) Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol 175(4):1298–1302
Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663
Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS (2009) Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-medicare analysis. Cancer 115(5):988–996
Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE, Teh BT, Kim HL (2010) Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 184(3):859–864
Hock LM, Lynch J, Balaji KC (2002) Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 167(1):57–60
Holmstrom B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Hugosson J, Stattin P (2010) Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden follow-up study. J Urol 184(4):1322–1327
Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR (2008) Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 113(1):78–83
Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (2006) 2004 WHO classification of the renal tumors of the adults. Eur Urol 49(5):798–805
Martinez CH, Martin P, Chalasani V, Williams AK, Luke PP, Izawa JI, Chin JL, Stitt L, Pautler SE (2011) How long can patients with renal cell carcinoma wait for surgery without compromising pathological outcomes? Can Urol Assoc J. doi:10.5489/cuaj.10035
Mason RJ, Abdolell M, Trottier G, Pringle C, Lawen JG, Bell DG, Jewett MA, Klotz L, Rendon RA (2011) Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol 59(5):863–867
Ming X, Ningshu L, Hanzhong L, Zhongming H, Tonghua L (2009) Value of frozen section analysis of enlarged lymph nodes during radical nephrectomy for renal cell carcinoma. Urology 74(2):364–368
Nuttall M, Cathcart P, van der Meulen J, Gillatt D, McIntosh G, Emberton M (2005) A description of radical nephrectomy practice and outcomes in England: 1995–2002. BJU Int 96(1):58–61
Rais-Bahrami S, Guzzo TJ, Jarrett TW, Kavoussi LR, Allaf ME (2009) Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int 103(10):1355–1358
Rathmell WK, Pruthi R, Wallen E (2010) Neoadjuvant treatment of renal cell carcinoma. Urol Oncol 28(1):69–73
Risberg T, Sørbye SW, Norum J, Wist EA (1996) Diagnostic delay causes more psychological distress in female than in male cancer patients. Anticancer Res 16(2):995–999
Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB (2003) An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169(1):110–115
Schlomer B, Figenshau RS, Yan Y, Venkatesh R, Bhayani SB (2006) Pathological features of renal neoplasms classified by size and symptomatology. J Urol 176(4 Pt 1):1317–1320
Sciarra A, Cattarino S, Salciccia S, Alfarone A, Gentilucci A, Parente U, Mariotti G, Innocenzi M, Gentile V (2011) The emerging role of targeted therapy in renal cell carcinoma (RCC): Is it time for a neoadjuvant or an adjuvant approach? Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2011.02.003
Simunovic M, Gagliardi A, McCready D, Coates A, Levine M, DePetrillo D (2001) A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario. CMAJ 165(4):421–425
Stec AA, Coons BJ, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE (2008) Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma–does it affect survival? J Urol 179(6):2152–2157
Subramonian KR, Puranik S, Mufti GR (2003) How will the two-weeks-wait rule affect delays in management of urological cancers? J R Soc Med 96(8):398–399
Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181(2):518–523
Yaycioglu O, Rutman MP, Balasubramaniam M, Peters KM, Gonzalez JA (2002) Clinical and pathologic tumor size in renal cell carcinoma; difference, correlation, and analysis of the influencing factors. Urology 60(1):33–38
Conflict of interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, K.H., You, D., Jeong, I.G. et al. The impact of delaying radical nephrectomy for stage II or higher renal cell carcinoma. J Cancer Res Clin Oncol 138, 1561–1567 (2012). https://doi.org/10.1007/s00432-012-1230-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-012-1230-2